NeoGenomics, Inc. announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the departure of former President of Inivata Clive Morris. Vishal will officially join NeoGenomics on May 23, 2022 and Dr. Morris will assist in the leadership transition over an appropriate handover period. Vishal Sikri has over 20 years of experience in the somatic diagnostics space and most recently was President of Oncology at Invitae.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.28 USD | -0.75% | +0.53% | -6.00% |
May. 02 | North American Morning Briefing : Stock Futures -3- | DJ |
Apr. 30 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.00% | 1.97B | |
-16.80% | 8.79B | |
+64.52% | 4.19B | |
-4.03% | 2.48B | |
-42.54% | 2.29B | |
-20.07% | 1.56B | |
-41.24% | 1.22B | |
+10.26% | 1.13B | |
+18.74% | 933M | |
-11.26% | 910M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- Neogenomics, Inc. Announces Executive Changes, Effective May 23, 2022